Aptose Biosciences (APS) Stock Price, News & Analysis

Company Overview

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

Key Stats

• Today's Range: C$0.32 to C$0.35
• 50-Day Range: C$0.24 to C$0.55
• 52-Week Range: C$0.19 to C$2.94
• Volume: 28,301 shs
• Average Volume: 25,841 shs
• Market Capitalization: C$5.70 million
• P/E Ratio: N/A
• Dividend Yield: 0.39%
• Price Target: N/A
• Consensus Rating: N/A

APS Stock Analysis - Frequently Asked Questions

How have APS shares performed this year?

Aptose Biosciences' stock was trading at C$0.33 on January 1st, 2025. Since then, APS stock has decreased by 3.1% and is now trading at C$0.32.
View the best growth stocks for 2025 here.

How do I buy shares of Aptose Biosciences?

Shares of APS stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

What other stocks do shareholders of Aptose Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Aptose Biosciences investors own include Aptose Biosciences (APTO), Aurinia Pharmaceuticals (AUPH), NVIDIA (NVDA), Advanced Micro Devices (AMD), Vistagen Therapeutics (VTGN), BlackBerry (BB) and Micron Technology (MU).

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: TSE:APS
• CUSIP: N/A
• CIK: N/A
• Web: aptose.com
• Phone: +1-647-4799828
• Fax: N/A
• Employees: 31
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): C($5.78)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: C$-40,290,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -694.13%
• Return on Assets: -136.29%

Debt

• Debt-to-Equity Ratio: 670.80
• Current Ratio: 0.80
• Quick Ratio: 5.41

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: C$0.20 per share
• Price / Cash Flow: 1.60
• Book Value: C($0.12) per share
• Price / Book: -2.63

Miscellaneous

• Outstanding Shares: 18,110,000
• Free Float: N/A
• Market Cap: C$5.70 million
• Optionable: Not Optionable
• Beta: 1.36